GlobeNewswire
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
📈
AI Sentiment
Highly Positive
8/10
Latest updates and market news for BFRI
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
8/10
Share this news page